{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T20:54:22Z","timestamp":1782680062461,"version":"3.54.5"},"reference-count":194,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T12:53:05Z","timestamp":1613047985000},"page":"103-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel therapies targeting cutaneous T cell lymphomas and their microenvironment"],"prefix":"10.1053","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-2410","authenticated-orcid":false,"given":"John C.","family":"Reneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am J Hematol"},{"issue":"31","key":"10.1053\/j.seminhematol.2021.02.002_bib0002","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0004","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.002_bib0005","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1053\/j.seminhematol.2021.02.002_bib0007","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.02.002_bib0008","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"10094","key":"10.1053\/j.seminhematol.2021.02.002_bib0009","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1053\/j.seminhematol.2021.02.002_bib0012","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in Sezary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.002_bib0013","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-18-3309","article-title":"Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression","volume":"25","author":"Borcherding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.002_bib0014","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0015","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.002_bib0016","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.002_bib0017","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast cells play a protumorigenic role in primary cutaneous lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdermsci.2012.07.007","article-title":"Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma","volume":"68","author":"Sugaya","year":"2012","journal-title":"J Dermatol Sci"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archderm.140.9.1057","article-title":"Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas","volume":"140","author":"Tancrede-Bohin","year":"2004","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.semdp.2016.11.002","article-title":"A new molecular paradigm in mycosis fungoides and Sezary syndrome","volume":"34","author":"Elenitoba-Johnson","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0021","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fcell.2020.00851","article-title":"Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma","volume":"8","author":"Stolearenco","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1523-1747.ep12494184","article-title":"Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins","volume":"98","author":"Tokura","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2017.10.028","article-title":"Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma","volume":"138","author":"Fanok","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0024","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2006-04-017863","article-title":"Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins","volume":"109","author":"Woetmann","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-065X.2008.00681.x","article-title":"The bacterial superantigen and superantigen-like proteins","volume":"225","author":"Fraser","year":"2008","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.002_bib0028","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cncr.27740","article-title":"Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series","volume":"119","author":"Jahan-Tigh","year":"2013","journal-title":"Cancer"},{"issue":"16","key":"10.1053\/j.seminhematol.2021.02.002_bib0029","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24564","article-title":"A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome","volume":"91","author":"Hanel","year":"2016","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1053\/j.seminhematol.2021.02.002_bib0031","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood.2019002790","article-title":"ECP in the spotLIGHT","volume":"134","author":"Wilcox","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0032","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/ajh.22139","article-title":"Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Wilcox","year":"2011","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0033","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0034","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-016-0201-6","article-title":"Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders","volume":"4","author":"Phillips","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0035","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","article-title":"Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.002_bib0036","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2021.02.002_bib0037","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0038","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0039","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0041","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genom Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0042","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0043","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","article-title":"Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma","volume":"1","author":"Bar-Sela","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"17","key":"10.1053\/j.seminhematol.2021.02.002_bib0044","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0045","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0046","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.002_bib0047","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.002_bib0048","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/leu.2015.340","article-title":"Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)","volume":"30","author":"Schuler","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.002_bib0049","doi-asserted-by":"crossref","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.002_bib0051","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0052","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clim.2008.04.009","article-title":"CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet","volume":"128","author":"Xu","year":"2008","journal-title":"Clinical Immunology"},{"issue":"6168","key":"10.1053\/j.seminhematol.2021.02.002_bib0053","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.002_bib0054","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0056","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.4049\/jimmunol.0901284","article-title":"Ikaros is a regulator of Il10 expression in CD4+ T cells","volume":"183","author":"Umetsu","year":"2009","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0057","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3389\/fimmu.2017.01773","article-title":"The CXCR4-STAT3-IL-10 Pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomide","volume":"8","author":"Shaim","year":"2017","journal-title":"Front Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0058","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.002_bib0059","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response","volume":"117","author":"Chanan-Khan","year":"2011","journal-title":"Cancer"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2021.02.002_bib0060","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2019-126358","article-title":"Phase 1 results of anti-PD-ligand 1 (durvalumab) & lenalidomide in patients with cutaneous T cell lymphoma and correlation with programmed death ligand 1 expression and gene expression profile","volume":"134","author":"Querfeld","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0061","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.002_bib0062","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0063","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0064","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood-2015-02-625251","article-title":"Mogamulizumab: 2 birds, 1 stone","volume":"125","author":"Wilcox","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and Sezary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0066","article-title":"Colony-stimulating factor 1 receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-cell lymphoma viability","author":"Murga-Zamalloa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.002_bib0067","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"32","key":"10.1053\/j.seminhematol.2021.02.002_bib0068","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0069","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol"},{"issue":"17","key":"10.1053\/j.seminhematol.2021.02.002_bib0071","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.002_bib0072","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in Sezary syndrome with SIRPalphaFc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0073","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1182\/blood-2018-99-116915","article-title":"Intralesional administration of the CD47 antagonist TTI-621 (SIRP\u03b1Fc) induces responses in both injected and non-injected lesions in patients with relapsed\/refractory mycosis fungoides and S\u00e9zary syndrome: interim results of a multicenter phase I trial","volume":"132","author":"Querfeld","year":"2018","journal-title":"Blood"},{"issue":"7651","key":"10.1053\/j.seminhematol.2021.02.002_bib0074","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0076","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","article-title":"Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors","volume":"32","author":"Qu","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0077","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/epi.15.118","article-title":"Histone deacetylase inhibitors as immunomodulators in cancer therapeutics","volume":"8","author":"Shen","year":"2016","journal-title":"Epigenomics"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0078","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2011-10-292003","article-title":"Histone\/protein deacetylases and T-cell immune responses","volume":"119","author":"Akimova","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.02.002_bib0079","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1158\/0008-5472.CAN-09-1456","article-title":"Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824","volume":"69","author":"Vo","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0080","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/sj.jid.5701216","article-title":"Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma","volume":"128","author":"Murakami","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0081","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V96.12.3847","article-title":"Up-regulation of costimulatory\/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells","volume":"96","author":"Maeda","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0082","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imm.12136","article-title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma","volume":"140","author":"Cycon","year":"2013","journal-title":"Immunology"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.002_bib0083","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","article-title":"Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate","volume":"65","author":"Armeanu","year":"2005","journal-title":"Cancer Res"},{"issue":"32","key":"10.1053\/j.seminhematol.2021.02.002_bib0084","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0085","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.002_bib0086","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0087","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0088","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0089","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2021.02.002_bib0091","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.002_bib0092","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0093","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7577","key":"10.1053\/j.seminhematol.2021.02.002_bib0094","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-143252","article-title":"A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0096","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0097","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1346-8138.12852","article-title":"CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis","volume":"42","author":"Sugaya","year":"2015","journal-title":"J Dermatol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0098","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.002_bib0099","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.002_bib0100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11899-011-0096-8","article-title":"CD30+ neoplasms of the skin","volume":"6","author":"Duvic","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0102","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0103","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0959-8049(96)00327-9","article-title":"Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies","volume":"33","author":"Nichols","year":"1997","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10428194.2012.706286","article-title":"Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sezary syndrome","volume":"54","author":"Prince","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0105","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0106","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0107","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.002_bib0108","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V124.21.3097.3097","article-title":"A dose finding lead-in study of E7777 (diphtheria toxin fragment-interleukin-2 fusion protein) in persistent or recurrent cutaneous T-cell lymphoma (CTCL)","volume":"124","author":"Duvic","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0109","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/cas.13513","article-title":"E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma: a phase I study","volume":"109","author":"Ohmachi","year":"2018","journal-title":"Cancer Sci"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2021.02.002_bib0110","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2019-121723","article-title":"Phase 2 study of E7777, a diphtheria toxin fragment-interleukin-2 fusion protein, in Japanese patients with relapsed or refractory peripheral and cutaneous T-cell lymphoma","volume":"134","author":"Maruyama","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0111","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0112","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0113","first-page":"506","article-title":"IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases","volume":"126","author":"Strauchen","year":"1987","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0114","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1309\/AJCP6Q7QMUVGMVMF","article-title":"Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children","volume":"132","author":"Gualco","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The four types of Tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0117","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0118","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2018-99-115986","article-title":"Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a phase 1 study of relapsed\/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma","volume":"132","author":"Collins","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"10.1053\/j.seminhematol.2021.02.002_bib0119","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hon.134_2630","article-title":"The anti-CD25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines","volume":"37","author":"Spriano","year":"2019","journal-title":"Hematol Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2021.02.002_bib0120","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood-2017-06-792382","article-title":"KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting","volume":"130","author":"Battistella","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0121","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0122","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0123","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2018-99-115269","article-title":"Clinical and biological evaluation of the novel CD30\/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with cutaneous presentation: a biomarker phase Ib\/IIa study (NCT03192202)","volume":"132","author":"Sawas","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140096","article-title":"Clinical and biological evaluation of the novel CD30\/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with cutaneous presentation: a biomarker phase Ib\/IIa study (NCT03192202)","volume":"136","author":"Sawas","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0125","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0126","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0127","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.002_bib0128","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0129","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.002_bib0130","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","article-title":"Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission","volume":"150","author":"Watanabe","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.002_bib0131","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-15-3099","article-title":"Colony-stimulating factor-1 receptor is required for nurse-like cell survival in chronic lymphocytic leukemia","volume":"22","author":"Polk","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6035","key":"10.1053\/j.seminhematol.2021.02.002_bib0132","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1126\/science.1204351","article-title":"Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation","volume":"332","author":"Jenkins","year":"2011","journal-title":"Science"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.002_bib0133","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.002_bib0134","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","article-title":"PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas","volume":"18","author":"Laimer","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1470-2045(05)70213-8","article-title":"Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified","volume":"6","author":"Piccaluga","year":"2005","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0136","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/leu.2014.50","article-title":"Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway","volume":"28","author":"Piccaluga","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"10.1053\/j.seminhematol.2021.02.002_bib0137","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0138","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2010-09-305425","article-title":"CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM\/TSP","volume":"117","author":"Ju","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0139","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/jid.2011.293","article-title":"Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome","volume":"132","author":"van der Fits","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0141","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpainsymman.2012.01.012","article-title":"Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma","volume":"45","author":"Wright","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0142","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Cedeno-Laurent","year":"2015","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0144","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1189\/jlb.3MR0117-033R","article-title":"The IL-31\/IL-31 receptor axis: general features and role in tumor microenvironment","volume":"102","author":"Ferretti","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2021.02.002_bib0145","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.002_bib0146","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/bloodadvances.2020001756","article-title":"JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL","volume":"4","author":"Yumeen","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2021.02.002_bib0147","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0148","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2006-12-061507","article-title":"Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome","volume":"110","author":"Shin","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0149","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/1078-0432.CCR-14-3322","article-title":"The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL)","volume":"21","author":"Litvinov","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"issue":"193","key":"10.1053\/j.seminhematol.2021.02.002_bib0151","doi-asserted-by":"crossref","first-page":"ra66","DOI":"10.1126\/scisignal.2001821","article-title":"ITK controls the spatiotemporal organization of T cell activation","volume":"4","author":"Singleton","year":"2011","journal-title":"Sci Signal"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0152","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2004.06.009","article-title":"Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet","volume":"21","author":"Miller","year":"2004","journal-title":"Immunity"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.002_bib0153","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-16-1996","article-title":"T-cell receptor signaling activates an ITK\/NF-kappaB\/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0154","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/bloodadvances.2017011916","article-title":"Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-137782","article-title":"Cpi-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma","volume":"136","author":"Khodadoust","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2021.02.002_bib0156","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.002_bib0157","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.002_bib0158","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.2012.068510","article-title":"Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas","volume":"98","author":"Martin-Sanchez","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0159","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0160","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.002_bib0161","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma","volume":"189","author":"Huang","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0162","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0163","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2018-99-112757","article-title":"Pooled safety analysis and efficacy of tenalisib (RP6530), a PI3K\u03b4\/\u03b3 inhibitor, in patients with relapsed\/refractory lymphoid malignancies","volume":"132","author":"Iyer","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.002_bib0164","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of tenalisib (RP6530), a dual PI3K delta\/gamma inhibitor in patients with relapsed\/refractory T-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.002_bib0165","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0166","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2021.02.002_bib0167","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1182\/blood-2008-08-176024","article-title":"Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.002_bib0168","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.002_bib0169","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","article-title":"Histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"Dermatol Clin"},{"issue":"23","key":"10.1053\/j.seminhematol.2021.02.002_bib0170","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/MCB.01481-08","article-title":"Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1","volume":"29","author":"Chen","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.002_bib0171","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Sors","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0172","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/1078-0432.CCR-07-1419","article-title":"Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents","volume":"14","author":"Sors","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0173","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/hupa.2000.20370","article-title":"Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis","volume":"31","author":"Izban","year":"2000","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0174","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.onc.1208212","article-title":"Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma","volume":"24","author":"Nasr","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1541-7786.MCR-10-0368","article-title":"Bortezomib induces nuclear translocation of IkappaBalpha resulting in gene-specific suppression of NF-kappaB\u2013dependent transcription and induction of apoptosis in CTCL","volume":"9","author":"Juvekar","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"27","key":"10.1053\/j.seminhematol.2021.02.002_bib0176","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0177","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/ajh.24895","article-title":"A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas","volume":"92","author":"Boonstra","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.002_bib0178","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.002_bib0179","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-17-0848","article-title":"ASTX660, a novel non-peptidomimetic antagonist of cIAP1\/2 and XIAP, potently induces TNFalpha-dependent apoptosis in cancer cell lines and inhibits tumor growth","volume":"17","author":"Ward","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.002_bib0180","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1158\/1078-0432.CCR-18-3802","article-title":"Dual antagonist of cIAP\/XIAP ASTX660 sensitizes HPV(-) and HPV(+) head and neck cancers to TNFalpha, TRAIL, and radiation therapy","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"16 suppl","key":"10.1053\/j.seminhematol.2021.02.002_bib0181","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/1538-7445.AM2020-5542","article-title":"ASTX660, a non-peptidomimetic antagonist of cIAP1\/2 and XIAP, enhances immune mediated tumor killing and induction of immunogenic cell death","volume":"80","author":"Ferrari","year":"2020","journal-title":"Cancer Res"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0182","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-19-1430","article-title":"A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma","volume":"26","author":"Mita","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12 suppl","key":"10.1053\/j.seminhematol.2021.02.002_bib0183","article-title":"Abstract A072: preliminary results of ASTX660, a novel non-peptidomimetic cIAP1\/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma","volume":"18","author":"Hollebecque","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0184","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.02.002_bib0185","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1182\/blood-2011-06-358382","article-title":"Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)","volume":"118","author":"Ralfkiaer","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0186","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.molonc.2011.02.003","article-title":"miRNA expression profiling of mycosis fungoides","volume":"5","author":"van Kester","year":"2011","journal-title":"Mol Oncol"},{"issue":"5824","key":"10.1053\/j.seminhematol.2021.02.002_bib0187","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1139253","article-title":"Requirement of bic\/microRNA-155 for normal immune function","volume":"316","author":"Rodriguez","year":"2007","journal-title":"Science"},{"issue":"1-2","key":"10.1053\/j.seminhematol.2021.02.002_bib0188","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0008-8749(02)00506-3","article-title":"T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene","volume":"217","author":"Haasch","year":"2002","journal-title":"BIC Cell Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.002_bib0189","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1073\/pnas.1101795108","article-title":"Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer","volume":"108","author":"Tili","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"15","key":"10.1053\/j.seminhematol.2021.02.002_bib0190","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1073\/pnas.1002472107","article-title":"Modulation of mismatch repair and genomic stability by miR-155","volume":"107","author":"Valeri","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"15","key":"10.1053\/j.seminhematol.2021.02.002_bib0191","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood-2009-06-222794","article-title":"Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma\/leukemia","volume":"114","author":"Yamanaka","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.002_bib0192","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2021.02.002_bib0193","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2018-99-119861","article-title":"Phase 1 trial of cobomarsen, an inhibitor of Mir-155","volume":"132","author":"Querfeld","year":"2018","journal-title":"Blood."},{"key":"10.1053\/j.seminhematol.2021.02.002_bib0194","series-title":"Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma","author":"Moskowitz AJ","year":"2019"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:27:21Z","timestamp":1758522441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":194,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000123"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies targeting cutaneous T cell lymphomas and their microenvironment","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}